

CURRICULUM VITAE - MEMORIU DE ACTIVITATE

Nume: GRIGORESCU

Prenume: ALEXANDRU CĂLIN

Nascut la 01 02 1955 Bucuresti

Liceul Gh. Lazar Bucuresti 1974

Facultatea de medicina "Carol Davila" Bucuresti 1981

POZIȚIA PREZENTĂ:

Sef Compartiment Oncologie Medicala, Spitalul Clinic de Nefrologie "Carol Davila"

Cercetător științific gradul I prin ordinul MECTI nr. 4506, 22 iulie 2010

Doctor abilitat 2014 – Ordin MS

Doctor în științe medicale 2002

Medic primar Oncologie Medicală, Institutul Oncologic București 1995

Competență bronhologie 1991, Institutul Marius Nasta-Bucuresti

Competență îngrijiri paliative 2005- „Casa Sperantei” Brasov.

Reprezentant al Romaniei in Grupul de Paliatie al Societații Europene de Oncologie Medicală(ESMO-PCWG) 1999-2020

Reprezentant național în Societatea Internațională de geriatrie oncologică 2010- 2020

Membru al Societații Americane de Oncologie Clinică

Membru al Societații Internaționale de Studiu al Cancerului Bronhopulmonar (IASLC)

Membru al Societații Europene de Îngrijiri Paliative

Membru in Comitetul Director al Societații Naționale de Oncologie Medicală din Romania (SNOMR), Fost presedinte executiv al societatii 2010- 2020

Expert al Comisiei Europene in Programul de oncologie HORIZON 2020, 2015-2020

Sef de sectie „Oncologie Medicala 2”IOB 2017-2020

Coordonator al „Centrului desemnat de ESMO pentru integrarea Oncologiei Medicala cu Ingrijirile Paliative” in IOB 2015- 2020.

Membru in Advisory Board al revistei „FramingHam on lung cancer”

Redactor sef al revistei „Oncolog Hematolog”

Peer reviewer in F1000

Peer reviewer „Asia Pacific Journal of Oncology”.

Peer reviewer „Translational Oncology Journal”

EDUCAȚIE:

1974 Liceul “Gheorghe Lazar”, București

1981 Absolvent al Facultății de Medicină Generală “Carol Davila”– București

1981 1984 Stagiatură: Spital “Ion Cantacuzino”- București

1984 1988 Medic de medicină generală: Jud. Bacău

1988 Admis prin concurs pentru secundariat în Oncologie și chimioterapie (Oncologie Medicală) la Institutul Oncologic București.

1991 Specialist Oncologie Medicală

1991 Competență bronhologie

1995 Medic primar Oncologie Medicală

2002 Susținerea tezei de doctorat –iulie- București

2005 Competență îngrijiri paliative

STAGII , CURSURI, EXAMENE

1990 Stagiu de bronhologie Institutul național de pneumologie « Marius Nasta »

1991 amen de specialist în Oncologie Medicală

1991 Obținerea titlului de cercetător în oncologia clinică

1993 Aprilie.- Junie.) Stagiu practic de oncologie medicală și bronhoscopie intervențională la Spitalul Laennec (Nantes – France)

1994 Curs de “Biologie moleculară pentru medicii clinicieni” (Ascona Switzerland)

1995 Admis pentru doctorat cu tema “Cancerul Bronhopulmonar fără celule mici avansat”. Institutul de Pneumoftiziologie Marius Nasta București, coordonator științific Prf.Dr. Emil Corlan UMF ”Carol Davila ”

1995. Iunie, stagiul de curieroterapie endobronșică, Hôpital Guillaume et René Laennec (Nantes, Franța).

1997 Curs de bună practică clinică în Oncologia Medicală “Good Clinical Practice (GSP) în Medical Oncology” – Copenhaga, Danemarca, 20-25 octombrie .

1998 Examen de promovare ca Cercetător științific principal gradul III.(Academia Romana de Medicina)

1998 Curs ESMO: “Reading, Writing and Randomised Trials” Budapesta, 28-31 octombrie.

1999-2000 Curs româno francez de psihooncologie – București- Diplomă de absolvire, referat absolvire.

2001 “Oncology Speakers Training Workshop Meeting” – Praga 6-8 septembrie

2002 Susținerea tezei de doctorat, iulie Bucuresti

2004 Obținerea prin examen a titlului de cercetător științific gradul II. - Validare nr. 1201/18 02 2003(Academia Romana de Medicina)

2004 Advanced course in thoracic tumors" Rhodes /Greece iunie 16 /19 iunie.

2006 Community in practice, Actualizarea cunoștințelor în diagnosticul și tratamentul cancerului bronhopulmonar – Hamburg, octombrie 2006

2009 ESMO grant în îngrijiri paliative - St. Galen Elveția

2009 Curs de bună practică clinică- St Galen –Elveția

2010- Examen cercetător științific gradul I, WIRA -SA

PARTICIPIRI LA CONFERINȚE ȘI CONGRESE (vezi anexa)

ACTIVITĂȚI PROFESIONALE

1991 Organizarea laboratorului de endoscopie bronșică din Institutul Oncologic București

1996 Membru fondator al “Central Eastern European Oncology Group” condus de Prof. Heine H. Hansen, Danemarca.

1996-2005 **Reprezentant al Romaniei în “ESMO (European Society for Medical Oncology) Central Eastern European Task- Force”**. Grup cu următoarele atribuții:

- identificarea mijloacelor care să ducă la recunoașterea Oncologiei Medicale ca specialitate de sine stătătoare,
- însușirea în vederea organizării unui grup de studii clinice, concretizată în înființarea : “Central Eastern European Oncology Group”,
- activitate de inițiere în organizarea de simpozioane, cursuri de oncologie medicală și nursing oncologic, concretizată în organizarea a două cursuri sub egida ESMO în România,
- stabilirea unor legături între ESMO și societățile naționale de oncologie medicală.

1998 Coorganizator și lector al cursului Societății Europene de Oncologie Medicală (ESMO): “Cytostatic agents delivery and toxicity”, Sinaia- Romania.

1999 Desemnat Reprezentant Național al Romaniei în Societatea Europeană de Oncologie Medicală (Primul Reprezentant Național al României în această societate)

2000 Membru fondator al ESMO- PCWG (Paliative Care Working Group)

2001 Președinte de curs și lector pentru ESMO course “Reading Writing Clinical Trials”- Sinaia, Romania (5-7septembrie)

2002 Copreședinte al sesiunii de psihooncologie a Congresului Societății Europene de oncologie medicală.(Nice /Franța 18-22 Octombrie).

2003 Membru în secretariatul “Central European Lung Cancer Conference” Viena, 1- 4 septembrie.

2001 Membru în comitetul de organizare al cursurilor ESMO din Programul educațional : « 5x5x5 »

2010 Obținerea pentru IOB a titlului de “Centru desemnat de ESMO pentru integrarea Oncologiei Medicale cu Îngrijirile Paliative” pentru Institutul Oncologic Buciurești

2009 – prezent :Reprezentant Național în Societatea Internațională de Geriatrie Oncologică (SIOG)www.siog.otg

2012-2013 Membru al grupului de prevenire și diagnostic precoce al Societății Internaționale de studiu al Cancerului Pulmonar (IASLC)

2013 – prezent: Membru al Societății F1000, ca post peer review- er al publicațiilor de oncologie, gerontooncologie, paliativă.

CERCETARE:

1. Grant Spital Spitalul Laennec (Nantes – France) oncologie medicala 1993
2. Coinvestigator în studiul clinic cu monitorizare internațională: “5-Fluorouracilul în bolus sau perfuzie de scurtă durată în cancerul de colon avansat” în cadrul “Central Eastern European Oncology Group” (1998).
3. 2001 Director proiect de cercetare sub egida Academiei de Științe Medicale cu titlul: Studiu clinic controlat de faza a II-a privind tratamentul asociat chimio-radioterapic față de chimio-radioterapia plus curieterapia endobronșică în cancerul bronho-pulmonar inoperabil cu obstrucție bronșică” care face obiectul contractului nr. 048/22.10.2001 încheiat între Academia de Științe Medicale – UCPN VIASAN și Institutul Oncologic Prof.dr. Alex.Trestioreanu București,

4. Elaborare design și Investigator principal în studiul național “Gemzar plus vinorelbină urmat de gemzar plus ifosfamidă față de gemzar plus cisplatin în cancerul bronhopulmonar fără cellule mici avansat
5. Studiul privind influența modularii imune cu Cantastim în cancerul mamar și pulmonar în colaborare cu Institutul Cantacuzino 2004.
6. Coordonator program IOB în grantul obținut de la Academia Medicală: “Tehnologie Avansată de Tratament A Pleureziilor Maligne Prin Termochimioterapie Intrapleurală”, <H-Tech Tcip>, Nr 3, 84, 2006
7. Activitate de cercetare în cadrul ESMO-PCWG 2000-2012.
8. Director proiect cercetare WIRA-SA 2010
9. 2010 Coordonator proiect cercetare Wira SA: “Ponderea apariției tumorilor canceroase în cadrul colectivelor de muncă în centralele electrice, în special de congenerare din deșeurii”
10. Grant ESMO cercetare în îngrijiri paliative 2009, St. Galen –Elveția, Studiu privind integrarea oncologiei medicale cu îngrijirile paliative.
11. Reprezentant al Institutului Oncologic București în proiectul de cercetare Elveția –Romania.2012- 2015.
12. Studiu asupra utilizării chestionarului IPOS într-o singură instituție (IOB) pentru screeningul necesității de paliativ a pacienților oncologici 2020.
13. Studiu de validare a chestionarului de apreciere a fragilității pacienților în vârstă tratați la unitatea de oncologie medicală din Spitalul de Nefrologie “Carol Davila” București.

>

Studii clinice(selectie) :

Programul / Proiectul	Funcția	Perioada
Phase II study: Gemcitabine monotherapy in advanced non small lung cancer, Elly Lilly 1997	coinvestigator	1997 -1999
5 Fluorouracil in shot perfusion versus bolus administration , Cenrtal Eastern European Oncolgy Group 1998	Investigator principal	1998- 1999
Phase III international study of oral Topotecan in second line of advanced small cell lung cancer, Glaxo-Smithkline 2001	Investigator principal	2001-2003
Studiu de faza a II-a, Gemcitabina plus cisplatin versus gemcitabina plus vinorelbina urmată de gemcitabina plus ifosfamidă în administrare secvențială 2002, Elly Lilly	Investigator principal	2002 -2004
Studiul internațional ChEST, Preoperator chemotherapy in Early stage non small cell lung cancer, Elly Lilly	Investigator principal	2003-2005
Studiul de faza a II-a, randomizat privind administrarea de extract de ecidivă pentru ameliorarea durerii în cancerul avansat. 2004	Investigator principal	2004

Studiul international de faza a IV-a privind chimioterapia de faza a II-a cu tarceva., Roche.	Investigator principal	2005-prezent
Studiu clinic controlat de faza a II-a privind tratamentul asociat chimio-radioterapic fata de chimio-radioterapia plus curieterapia endobronsica în cancerul bronho-pulmonar inoperabil cu obstructie bronsica care face obiectul contractului nr. 048/22.10.2001 încheiat între Academia de stiinte Medicale – UCPN VIASAN si Institutul Oncologic Prof.dr. Alex.Trestioreanu Bucuresti	Director de proiect	2002- 2004
Studiul international de faza a II-a privind hormonoterapia cu inhibitori selectivi de aromatază în cancerul mamar ecidivate sau metastatic. (2005).Intarcia –USA	Investigator principal	2005-2006
Coinvestigator în studiul privind administrarea de anticorpi monoclonali (removab) pacientilor cu ascita neoplazică refractară la citostatice (2005),Fresenius –Germania	Subinvestigator	2005-2007
Tehnologie avansata de tratament a pleureziilor maligne prin termochimioterapie intrapleurala, Nr. 3 / 84 / oct. 2006	Coordonator proiect parteneriat IOB	2006- 2009
A Multi-center , Randomized , double-blind , Placebo-controlled, Phase 3 Study of Single –agent Tarceva following Complete Tumor Resection and with or without Adjuvant chemotherapy in patients with Stage IB-III A Non –Small Cell Lung Carcinoma who have EGFR –Positive Tumors	Investigator principal	2007-2008
A randomized withdrawal, active –and placebo –controlled , double –blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignant tumor- related pain. –Grunenthal	Investigator principal	2007-2008
Phase 2, randomized, open label, multicenter study of intradermal IMA 901 plus GM-CSF with or without low	Investigator principal	2007-2008

close cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable disease-immatics		
A Randomized Double blind Multicenter study of Denosumab Compared with Zoledronic Acid in the Treatment of Bone Metastasis in Men with Hormon –refractory prostate cancer.	Investigator principal	2008+2009
Studiu nonintervențional Eligard 7,5 mg și 22,5 mg pentru tratamentul cancerului avansat de proastă hormonodependent	Investigator principal	2009
Studiul DMS32212R - cancer bronhopulmonar avansat	Investigator principal	2009-2010
Studiul ML 20951, Tarceva (studiu original la propunerea investigatorului principal)	Investigator principal	2009-2010
Phase 2 randomized study of carboplatin /paclitaxel with or without CS -7017 in chemotherapy –naive subjects with metastatic non-small cell lung cancer, CS7017-A+U202	Investigator principal	2010-2011
Studiul IUNO, (Erlotinib in cancerul bronhopulmonar metastatic)	Investigator principal	2012-2013
Studiul MSD “Palonosetronul in terapia antiemetică generată de citostatice cu efect hiperemetic mediu~	Investigator principal	2015-2014
Studiul Grunenthal: Cerebropradol-ul versus sulfatul de morfina in durerea medie si severa din cancer	Investigator principal	2014-2015
Studiul Academic sponsorizat de autoritatea academica elvetiana ZERZO	Coordonator al echipei din Bucuresti	2013-2015
Studiul Flaura in cancerul pulmonar avansat cu rezistență la EGFR	Investigator principal	2015-2016
Studiul international privind respectarea ghidurilor internationale privind medicatia antiemetică pentru chimioterapia antineoplazică	Investigator principal	2017-2020
Avelumab versus chemotherapy in advanced non-small lung cancer, phase III study	Investigator principal	2017-2020
Studiul observational national asupra Durvalumab-ului in cancerul	Investigator principal	2021

EXPERIENȚA DIDACTICĂ:

1. Lector în cursul organizat de ESMO (Societatea Europeană de Oncologie Medicală) "Cytostatic agents delivery and toxicity", Sinaia- Romania 1998. (Primul curs internațional organizat de IOB sub egida ESMO și primul curs cu traducere simultană engleză-română pentru medici oncologi și asistente).
2. Președinte de curs și lector în cursul ESMO: "Reading Writing Clinical Trials"- Sinaia, Romania (5-7septembrie 2001).
3. Co -preșdinte la sesiunea de psihooncologie din cadrul Congresului ESMO de la Nice -France 2002
4. Președinte de curs și lector în cursul ESMO: "Fundamentals in Medical Oncology" , Sinaia 2003.
5. Președinte de curs ESMO și lector: "Lung cancer and Head and neck tumors " Bucharest October 2004
6. Președinte de curs ESMO și lector în cursul: "Gastrointestinal malignancy", București 2005.
7. Președinte de curs și lector în Simpozionul SIOG)societatea internațională de Geriatrie Oncologică) - SNOMR (Societatea Națională de Oncologie Medicală din Romania), Poiana Brașov 2006.
8. Lector în cadrul "Școlii Europene de Oncologie": "Masterclass in Palliative Cancer Care", Tbilisi –Georgia, 2007.
9. Lector în Simpozionul ESMO: "Palliative and Supportive care in Medical Oncology", București 2007.
10. Lector si președinte de simpozion: "ASCO-SIOG-SNOMR Symposium" Poiana Brașov 2009
11. Președinte de simpozion și lector în Simpozionul ESMO: "Update in Medical Oncology", Poiana Brașov 2010.
12. Președinte simpozion și lector: "Palliative Care" în cadrul "Zilelor științifice ale IOB" București 2010.
13. Lector și președinte de simpzion: "New trend in Medical Oncology", ASCO-SNOMR Symposium , Poiana Brașov 2011.
14. Lector și președinte simpozion internațional: "Integration of Palliative Care with Medical Oncology", în cadrul "Zilelor științifice ale IOB". București 2011.
15. Coordinator și lector în "INTERNATIONAL SYMPOSIUM ASCO-SNOMR": "Lung cancer a change for new therapies", 12- 13 October 2012 Poiana Brasov – ROMANIA

16. BREAST CANCER ACTUAL KNOWLEDGE AND NEW STANDARDS TO IMPROVE SURVIVAL AND QUALITY OF LIFE, ESMO-SNOMR Symposium Coordinator: Alexandru C. Grigorescu MD, PhD, SRDI Poiana Brasov _18-19 octombrie 2013
17. Lector în cursul "Tratamentul multimodal al cancerului mamar" Congresul Național de Chirurgie – Sinaia mai 2014
18. Lector în cursul: "Tratamentul complex al cancerului de rect" Congresul Național de Chirurgie – Sinaia mai 2014
19. Microcurs ESMO-MASCC-SNOMR Importance of supportive care in the world of oncology today 2017 –Poiana Brasov
20. Prezentare: "Inhibitorii de tirozininkinaza in cancerul pulmonar avansat"-Poiana Brasov 2018
21. Cursul de specializare in oncologie a asistentilor medicali 2019-2020, organizat de Școala Națională de Sănătate Publică 2020-2021

LISTA de LUCRARI

Prezentari in manifestari stiintifice in tara:

1. Problems bronchoscopy in diagnosis of lung cancer - Colloquium Romanian - French Pneumology, Bucharest, October 1991.
2. Evolving clinical and therapeutic aspects in carcinomatous mastitis, Grigorescu Alexander Mogoș Ion, Done {Serban, Doina Spataru Conference națională de oncology, Craiova 8 to 9 October 1992.
3. Diagnosis and treatment of advanced lung cancer, Alexandru Grigorescu, John Mogoș, {Serban done, Dana Stănculeanu, Scientific days of Institute of Oncology Bucharest 1993.
4. The combination of radiotherapy and chemotherapy in NSCLC. Alexandru Grigorescu, Maricica Palade, Mircea Savu, Anton Ionescu, Days radiotherapy, Bucharest May 24 to 25, 1994
5. CEA and CA125 in the diagnosis, monitoring and development of NSCLC. Alexandru Grigorescu, Eliza Mănoiu, Nicholas Stafidov, Days radiotherapy session of IOB. 26 to 27 May 1995
6. Pilot study on the use of interferon in aerosols or introduced by bronchoscopy in the treatment of obstructive endobronchial neoplastic syndrome, Alexandru Grigorescu, națională de Oncology Conference, Poiana Brasov, 24-25 October 1996.
7. Chemotherapy versus chemotherapy associated with biphosphonates in the treatment of pain in lung cancer with bone metastases, Alexandru Grigorescu, IOB științifică anuală Session, 29-30 May 1997.
8. Polychemotherapy regimens in non small cell lung cancer, administration protocol, tolerance, toxicity. Alexandru Grigorescu, National Cancer Congress, Poiana Brasov, 1997.

9. Randomized phase II trial: chemotherapy of carboplatin plus gemcitabine versus cisplatin and vinblastine in advanced NSCLC.
Alexandru Grigorescu, Nicolae Guțulescu, National Congress of Oncology, Bucharest October 14 to 16, 1999.
10. Open clinical study on the influence of chemotherapy on quality of life and survival of patients with advanced lung cancer,
Alexandru Grigorescu Nicolae Guțulescu.
11. Combination chemo-radiotherapy in mediastinal compression syndrome in cancer,
Alexandru Grigorescu, Xenia Bacinschi, Alin} Arle, first conferințănaționalăde medical oncology, Craiova - Căciulata 11 to 14 April 2002.
12. Ioan Popa, Alexandru Calin Grigorescu, Michael Gr Mark, Mona Marin ,Study of risk factors and survival in chronic diseases - statistical approach, Conference anniversary of the Institute of Public Health, Bucharest, June 12 to 13, 2003.
13. Grigorescu, T. Ciuleanu, Elena Firoiu, Delia Muresan, C. Davidescu, M. Ciochinaru, R. Curca, Roberta Rosca, Gabriela Teodorescu ,Sequential combination of gemcitabine plus vinorelbine followed by gemcitabine versus gemcitabine plus ifosfamide plus cisplatin in the treatment of non-small cell lung cancer stages III and IV, preliminary results of a randomized phase II study.
National Conference of Oncology, Durau, 10 - September 14, 2003, p34. T. A.
14. Doina Spataru, A. Grigorescu, Comparative study of adjuvant chemotherapy with 5 fluorouracil versus polychemotherapy in stage III gastric cancer, Scientific days of Institute of Oncology Bucharest November 2003.
15. Continuous infusion devices used in chemotherapy of digestive malignancies.
Scientific Days of Institute of Oncology "Prof. Dr. Ion Chiricuță» 9 to 10 October 2003.
16. "Organizing a center for clinical trials," communication training sessions continue in IOB. November 2003.

Publicatii in reviste Romanesti:

17. Alexandru Grigorescu, Assessing value of endoscopic bronchial issues in bronhopulmonar cancer evolution and prognosis., "Oncology and Radiotherapy" - Vol XXXII No. 1-1994, p 63
18. Alexandru Grigorescu, Constance Chiritescu, Endoscopic and citohistologic elements of association: inflamator-cronic syndrome - bronhopulmonar cancer, "Oncologia and radiotherapy" Vol XXXII, NO. 1, 1995, p 75-78.
19. Alexandru Grigorescu Nicolae Guțulescu, Delia Marta, {Serban Donea, Phase II study of

the etoposide plus cisplatin and ciclifosfamid in advanced lung cancer, "Oncology and Radiotherapy" Vol XXXII, NO. 2-3, 1995, p 35-40.

20.Alexandru Grigorescu, Eliza Mănoiu, Nicholas Stafidov, CEA and CA 125 in the diagnosis and monitoring of lung cancer treatment " Oncology and Raditherapy" 1996, vol 333 NO. 1, p 53-56.

21.Alexandru Grigorescu, impact of chemotherapy on quality of life of patients with advanced lung cancer, "Oncology and Radiotherapy" vol XXXII, 1996, NO. 2 to 3, p73-77.

22.Alexandru Grigorescu, recent data in the treatment of advanced lung cancer, "Clinical Toxicology Terapeuticăși", Vol II, No. 1, 1998, p 117.

23.Alexandru Grigorescu, colon cancer with liver metastases, case presentation. "Romanăde Oncology Review", vol XXXVI, NO. 1, 1999, P105.

24.N. Gutulescu, A.Grigorescu, D.Uta, A. Sherer, L Gebez, K.Krejcy, Gemcitabine in advanced lung cancer , Romanian Journal of Oncology, Volume XXXVI, No. 2, 1999, p 25.

25.Nicolae Guțulescu, Alexandru Grigorescu, Paclitaxel with cisplatin in NSCLC, Revista Romana de Oncologie, vol 36, no. 3, 1999, p :268-271.

26.A.Grigorescu, N. Draghici, N. Gutulescu, Taxol versus radiotherapy alone with radiotherapy in non-small cell lung cancer - pilot study, Supplement of Radiotherapy and Medical Oncology, Vol 36, No. 2, 1999.

27. Alexandru Grigorescu, Nicolae Guțulescu, Quick diagnosis and treatment of lung cancer, Romanian Journal of Oncology, Vol 37, No.1, 2000, p :15-23.

28.Alexandru Grigorescu, Niculina Draghici, Cornelia Nițipir, Nicholas Guțulescu, Emil Corlan, gemcitabinăși carboplatin chemotherapy with cisplatin and vinblastine in non small advanced lung cancer, stage III and IV controlled clinical trial phase III, Info medication, 9 / 2001, p: 40-45.

29.Alexandru Grigorescu Nicolae Guțulescu, Emil Corlan, open clinical study on the influence of chemotherapy on quality of life and survival of patients with lung cancer advanced (stages III and IV), Journal Românăde Oncology, vol 38, no. 2/2001, p :91-98.

30..Marilena Dinulescu Alexandru Grigorescu, Prevalence of microbial agents in bronchial aspirates in subjects with lung neoplasm, first Congress Foundation in collaboration with the Clinical Laboratory of Microbiology, Mamaia 29-May -25 June 2002.

31.Translation of ESMO guidelines "Romanian Journal of Oncology", March 2004.

32. A. Grigorescu, N. Wales pleurisies treatment of malignant lung cancer, hematology oncologist rev # 4 - 2008.

33. A. Grigorescu, News in the treatment of malignant melanoma, Oncolog Hematolog No. 3-2009.

34. A. Grigorescu, Chemotherapy of lung cancer in the elderly, Oncolog Hematolog, Year III, No. 6 March 2009, p 18-21.

35. A. Grigorescu, News in treatment of advanced gastric cancer, Oncolog Hematolog, Year III, No. 7 (2) 2009
- 36.A. Grigorescu, News in therapy of small cell lung cancer, Oncolog Hematolog, Year III, nr.9.4/2009
- 37.A. Grigorescu, Current clinical research in melanoma, Oncology Hematolog, Year III, nr.8.3 2009, p§26-28.
38. A. Grigorescu, "Policy of small steps", Hippocrates, December 2009, p 37.
39. A. Grigorescu, Clinical and therapeutic approach in refractory dyspnoea, Oncolog Hematolog, year IV, nr.13-4/2010
40. A. Grigorescu, Colon cancer chemotherapy, oncology, hematology, Year IV, 12.3/2010
41. A. Grigorescu, Targeted therapy in advanced renal cancer. Oncolog Hematolog, Nr14, 1/2011, p.23-25
- 42.A. Grigorescu, The management of advanced prostate cancer.Oncolog Hematolog, 15. 2/2011, p 16-18.
- 43.A. Grigorescu, Updates in small cell lung cancer therapy, Oncolog Hematolog, Nr20, 3/2012, p 32-34.
44. A. Grigorescu, International Symposium ASCO-SNOMR, Oncolog Hematolog 21. 4/2012.p. 12-13.
45. A. Grigorescu, "The success of failure" - Center for Integration of palliative care in medical oncology in the Institute of Oncology Bucharest, NR4 Hippocrates, December 2012. P20-23.

CARTI:

46. Alexander C Grigorescu, "Breviary of diagnosis and treatment of advanced lung cancer," Ed Bacovia, Bacau 2000, p 1-172.
47. Alexander C. Grigorescu, "Breviary of diagnosis and treatment of advanced lung cancer," second edition, Ed "Cartex 2000", Bucharest 2003.p 1-192.
48. Alexandru Grigorescu, Rodica Anghel and all, Principles of clinical trials in oncology, Ed Carol Davila – Bucharest 2006, p3-235.
49. Alexandru Grigorescu: "Respiratory Problems in" ESMO Hand book of Advanced Cancer Care ", Taylor & Francis Books Ltd, 2006, P97-104
50. Alexandru Grigorescu, Heine Hansen, Rodica Anghel, and all "ESMO Head and neck course, thoracic tumors," Carol Davila - Bucharest 2006, 1-238
51. Alexandru Grigorescu, Hans Joachim Small, Rodica Anghel, and all. "ESMO course, gastrointestinal malignancy," Ed Carol Davila, Bucharest 2007, 3-283
52. Alexandru Grigorescu, Nathan Cherny, Dana Stănculeanu and all "Palliative and supportive care in Medical Oncology" Ed Carol Davila Bucharest 2007, p3-11.p3-201
53. Alexandru Grigorescu, Medical Treatment of Advanced Lung Cancer, Editura Medicala, Bucharest 2008, p3-173

54. Alexandru Grigorescu, Lodovico Balducci, Florinel Badulescu, and all, 'Update in Medical Oncology Editura Medicala - Romania, 2011.p11-254.

55. Alexandru Grigorescu, **Management of Chemotherapy Complications in Gynecological Malignancy Treatments**, Ali Ayhan, Nicholas Reed, Murat Gultekin si Polat Dursun.,Textbook of Gynaecological Oncology, “ Gunes Publishing’ 2016.

56. Immunotherapy in Advanced Lung Cancer Treatment, October 2018, DOI: 10.5772/intechopen.77005, In book: Lung Cancer - Strategies for Diagnosis and Treatment License [CC BY 3.0](#)

Publicatii in reviste internationale:

57. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashegyi A, Yurasov S, Pérol M, Edward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N Syrigos, Tuncay Goksel, Keunchil Park, Vera Gorbunova, Ruben Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey V Orlov, Conrad R Lewanski, Michael Thomas, Paolo Bidoli, Shaker Dakhil, Steven Gans, Joo-Hang Kim, **Alexandru Grigorescu**, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, Maurice Péro

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial,

The Lancet, June 2014, DOI 10.1016/s0140-6736(14)60845

56. N. Magaya-Kalbermatten¹, P. Achimas-Cadariu², R. Curca³, A. Grigorescu⁴, D. Mosiou⁵, V. Porocho⁶, F. Strasser¹ **KEY INTERVENTIONS OF PALLIATIVE CANCER CARE (KI-PCC) - PATIENT PERCEIVED NEED AND REMEMBERED DELIVERY...**

Article in *Annals of Oncology* · September 2014

DOI: 10.1093/annonc/mdu350.11

57.**Alexandru C. Gigorescu**, Ioana N. Drăghici, Cornelia Nițipir, Nicolae Guțulescu, Emil Corlan, Gemcitabine(GEM) and carboplatin versus cisplatin (CDDP) and vinblastin (VLB) in advanced non-small –cell lung cancer (NSCLC) stages III and IV: a phase III randomized trial, *LUNG CANCER* 37(2002) 9-14.

58. [Ciuleanu T¹](#), [Stelmakh L](#), [Cicenas S](#), [Miliauskas S](#), [Grigorescu AC](#), [Hillenbach C](#), [Johannsdottir HK](#), [Klughammer B](#), [Gonzalez EE](#) *Lancet Oncol*. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study, 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.

59. **Alexandru C. Grigorescu, Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest, JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / JAN-MAR 2015 / VOL 3 | ISSUE 1, 10.4103/2224-4018.154291,**

60. **Alexandru C. Grigorescu** ,Short Review of “Phase II Study of Erlotinib Plus Gemcitabine in First-Line Treatment of Poor Prognosis, Advanced Non-Small Cell Lung Cancer(NSCLC) Patients”- 8 Years Letter, **World Journal of Research and Review (WJRR)**, ISSN:2455-3956, Volume-2, Issue-5, May 2016 Pages 15-17

61. **Alexandru C. Grigorescu**, Pemetrexed in third and fourth line chemotherapy for non-squamous non-small cell lung, Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 5(2) pp. 093-097, February, 2017 Available online <http://www.meritresearchjournals.org/mrms/index.htm> Copyright © 2017 Merit Research Journals *Original Research Article*

62. **A. C. Grigorescu**, *O.G. Negrea, D. Spătaru, Letters to editor*, JURNAL OF B.U.ON., VOL 8, NO 2, APRIL- JUN 2003, 193. (IF=0,6)

63. Nathan I. Cherny M.B.B.S.1,†,§, Raphael Catane M.D.2,§, Maurizio Tonato (Policlinico Divisione Oncologia Medica, Perugia, Italy); K. Winand Lange (Johanniter-Krankenhaus Rheingaus, Duisburg, Germany); Herbert Kappauf (Institut für Medizinische Onkologie, Nürnberg, Germany); **ALEXANDRU-CALIN GRIGORESCU** (Oncologic Institute of Bucharest, Bucharest, Romania); Sergei Tjulandin (Cancer Research Center, Moscow, Russia); Piotr Siedlecki (Marie Skłodowska-Curie Institute Cancer Center, Warszawa, Poland); Marco Maltoni (Department of Medical Oncology, Pierantoni Hospital, Forlì, Italy); Marianne Kloeke (Universitätsklinikum Essen, Essen, Germany); Kaija Holli (Department of Oncology, University Hospital, Tampere, Finland); Vladimir Bryuzgin (Cancer Research Center, Moscow, Russia); Dirk Schrijvers (Middelheim Hospital, Antwerp, Belgium); Özgür Özyilkan (Baskent University Faculty of Medicine, Ankara, Turkey); Martin Chasen (Richard Eek Sandton Oncology Centre, Pretoria, South Africa); Maria Wagnerova (University Teaching Hospital, Kosice, Slovak Republic); Janos Szanto (Debrecen Medical University, Debrecen, Hungary); and Joao Oliveira (Instituto Portugues de Oncologia, Lisboa Codex, Portugal).

Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer†

Report on a survey by the European Society of Medical Oncology taskforce on palliative and supportive care, CANCER, VOLUME 98, ISSUE 11, PAGES 2502–2510, 1 DECEMBER 2003

64. N. I. Cherny¹, R. Catane², P. A. Kosmidis³ and Members of the ESMO Palliative Care Working Group⁴, [Introduction by Heinz Ludwig, ESMO President](#), Policy on supportive and Palliative Care,

M. Tonato, Policlinico Divisione Oncologia Medica, Perugia, Italy; M. Maltoni, Pierantoni Hospital Department of Medical Oncology, Forlì, Italy; K. Winand Lange, Johanniter-Krankenhaus Rheinhausen, Duisburg, Germany; H. Kappauf, Institut für Medizinische Onkologie, Nürnberg, Germany; M. Kloke, Universitätsklinikum Essen, Essen, Germany; **A.-C. Grigorescu, Oncologic Institute of Bucharest**, Bucharest, Romania; S. Tjulandin, Cancer Research Center, Moscow, Russia; V. Bryuzgin, Cancer Research Center, Moscow, Russia; P. Siedlecki, M. Skledowska-Curie Institute Cancer Center, Warsaw, Poland; K. Holli, University Hospital Department of Oncology, Tampere, Finland; D. Schrijvers, Middelheim Hospital in Belgium, Antwerp, Belgium; Ö. Özyilkan, Baskent University Faculty of Medicine, Ankara, Turkey; M. Chasen, R. Eek Sandton Oncology Centre, Pretoria, South Africa; M. Wagnerova, University Teaching Hospital, Kosice, Slovak Republic; J. Szanto, Debrecen Medical University, Debrecen, Hungary; and J. Oliveira, Instituto Portugues, de Oncologia, Lisboa Codex, Portugal, Esmo.orgESMO, 2004

65. Iuliana Caras Æ **A. GRIGORESCU** Æ Crina Stavaru, D. L. Radu Æ I. Mogos Æ G. Szegli Æ Aurora Salageanu, Evidence for immune defects in breast and lung cancer patients, CANCER IMMUNOLOGY, IMMUNOTHERAPY, DECEMBER 2004, VOLUME 53, ISSUE 12, PP 1146-1152, CITED BY 57 - RELATED ARTICLES

66. **Alexandru Grigorescu**. Tudor Ciuleanu, Elena Firoiu A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naïve patients with stage III and IV non-small cell lung cancer(NSCLC), LUNG CANCER 2007 AUG; 57(2): 168-74, EPUB 2007, APR30

67. Ardizzoni, Andrea¹; Razis, Evangelia²; Lichinitser, Mikhail³; Yilmaz, Ugur⁴; Grigorescu, Alexandru C.⁵; Morero, José Luis⁶; Skrickova, Jana⁷; Cervantes, Guadalupe⁸; Gottfried, Maya⁹; Van Meerbeeck, Jan¹⁰, Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): B3-06, **International Journal of Radiation On**, Volume 78, Issue 5 , Pages 1407-1412, 1 December 2010, IF: 4,524

68. Cherny NI; on behalf of the Palliative Care Working Group of the European Society for Medical Oncology Nathan I. Cherny (Chair, Israel), Raphael Catane (Israel), Martin R. Chasen (Canada), **Alexandru-Calin Grigorescu (Romania)**, Marianne Kloke, (Germany), Ian Olver (Australia), Ozgur Ozyilkan (Turkey), Gudrun Marie Ilse Pohl (Austria), Carla Ripamonti (Italy) Maryna Rubach (Poland), Tamari Rukhadze (Georgia), Dirk Schrijvers (Belgium), Anna-Marie Stevens (United Kingdom), Florian Strasser (Switzerland), Maria Wagnerova (Slovakia). Factors influencing the attitudes and behaviors of oncologists regarding the truthful disclosure of information to patients with advanced and incurable cancer. PSYCHOONCOLOGY. 2010 SEP 28. [Epub ahead of print]

69. S. Tanneberger^{1*}, K. Hegedus², **A. Grigorescu**³, J. Luczak⁴, G. Biasco⁵ & F. Cavalli⁶ , Medical oncology recognized at EU level to allow free movement of doctors: progress and challenge, ANNALS OF ONCOLOGY ADVANCE ACCESS PUBLISHED APRIL 28, 2011

70. Dr Tudor Ciuleanu MD, Lilia Stelmakh MD b, Prof Saulius Cicenass MD c, Skaidrius Miliauskas MD d, **Prof ALEXANDRU CALIN GRIGORESCU** SR e, Carina Hillenbach MSc f, Hrefna Kristin Johannsdottir PhD f, Barbara Klughammer PhD f, Prof Emilio Esteban Gonzalez MD g, Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a

randomised multicentre, open-label, phase 3 study, THE LANCET ONCOLOGY, VOLUME 13, ISSUE 3, PAGES 300 - 308, MARCH 2012

71. **A. C. Grigorescu**, C. Bala, Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients, J BUON 2013; 18(1): 188-194 ISSN: 1107-0625 www.bu-on.org/jbuon

BSTRAȚII ÎN VOLUMELE CONFERINȚELOR INTERNAȚIONALE, REVISTE INDEXATE ÎN BAZE DE DATE INTERNAȚIONALE, RECENZII, PEERREVIEW -uri PUBLICATE ÎN REVISTE INDEXATE ÎN BAZE DE DATE INTERNAȚIONALE

72. PC (Paclitaxel, Cisplatin) or MECC (Metotrexat, Epirubicine, Cyclophosphamide, CCNU) as a Second Line Treatment for Non small Cell Lung Carcinomas (NSCLC). Abstract – Annals of Oncology, vol. 7, 1996, Supp 5 NR. 492, p 103.

73. Nonmorphinic analgesic combinations in pain treatment for cancer. European Journal of Cancer, vol. 35 Supp 4, Sept. 1999, a. 98.

74. Gemcitabine plus carboplatin (GCB) versus cisplatin plus vinblastin (CV) in stage IIIB-IV non-small cell lung cancer (NSCLC). Annals of oncology, vol 11, 2000, sup 4, abstract 499, p110.

75. Gemcitabine plus Carboplatin (Gcarb) versus Cisplatin plus Vinblastine (CV) in Patients (pts) with Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC), **A.C. Grigorescu**¹, I.N. Draghici¹, N. Gutulescu¹, E. Corlan², Citation: European Journal of Cancer Vol 37, Suppl. 6, October 2001, page 21

76. **L. Onet**, A. Grigorescu, Symptomatic treatment improve quality of life of patients with lung cancer, Citation: European Journal of Cancer Vol 37, Suppl. 6, October 2001, page 442

77. I. Pană, A. Grigorescu, Medical Oncology in Romania, Newsletter, 1/1996, p:7

78. Alexandru Grigorescu, “Course report: Cytostatic Agents – delivery and toxicity, an ESMO – EONS Course, Newsletter, 1/1999,p9.

79. Course report: Reading, Writing and Randomised Trials, Newsletter, 2/2001,p:7.

80. Alexandru Grigorescu, “Case report”, “Practical demonstration of pumps and I.V. lines”, “Controversial ways of administration i.p., i.a.”, în volumul “ESMO-EONS Course”: “Cytostatic Agents – delivery and toxicity, Sinaia Romania 1-3 octombrie 1998.

81. Alexandru Grigorescu, “Need for strategies in Evidence Based Medicine”, în volumul:”Reading, Writing and Randomized Trials”, Sinaia Romania, mai 2-5, 2001.

82. A. C. Grigorescu, N. I. Drăghici, L. M. Minea, N. Guțulescu, Gemcitabine (GEM) plus carboplatine (CBDCA) in sequential administration after etoposide (VP16) plus cisplatin(CDDP):a phase II study. American society of clinical oncology, vol 21, part 2 of 2, p 237b.

83. Alexandru Grigorescu, Roxana Pristavu, Nicolae Guțulescu, Influence of depression (D) in evolution of advanced non-small cell lung cancer (NSCLC) treated by chemotherapy with cisplatin (CDDP) plus etoposid (VP16) or Gemzar (G) plus carboplatin I, *Annals of Oncology*, vol 13,2002 Su8pplement 5,p186.
84. Alexandru C. Grigorescu, Roxana Pristavu, Tewodor Georgescu, Phase II studz of carboplatin(CBDCA) intravenous administration plus etoposid (VP16) in oral administration for patients (pt) with advanced non-small cell lung cancer (NSCLC), *Annals of Oncologz*, Supplement 3, vol 14, 2003.
85. Tudor Ciuleanu, Elena Firoiu, Alexandru Calin Grigorescu, Delia Ruta Muresan, Cristian Davidescu, Mihai Ciochinaru, Razvan Curca, Roberta Rosca, Gabriela Teodorescu, Tomas Scacel, Sequential Combination of Gemcitabine Plus Vinorelbine Followed bz Gemcitabine Plus Ifosfamide Versus Gemcitabine Plus Cisplatin in the Treatment of Stage III and IV Non-Small Cell Lung Cancer, Preliminarz Results of a Randomiyed Phase II Trial, *Lung Cancer*, vol 41, Supplement 2, August 2003, S 224.
86. Alexandru Calin Grigorescu, Claudia Bala, Ioan Popa, Nicolae Gutulescu, Correlation between overall survival and some characteristics of long survivors with advances non small lung cancer (NSCLC) stages IIIB and IV, a retrospective study, *Lung Cancer*, vol 41, Supplement 2, August 2003, S 288.
87. Course report “Fundamentals in Medical Oncology”, *ESMO News Letter* 2004
88. Brachytherapy plus chemotherapy in advanced non small cell lung cancer (NSCLC), *Lung Cancer supplement*, IX 2005, p76.
89. G. Teodorescu, T. Ciuleanu, A. Grigorescu, E. Firoiu and D. Ruta Muresan, P382 A randomized phase II trial of sequential gemcitabine plusvinorelbine followed by gemcitabine plus Ifosfamide versus gemcitabine plus cisplatin in the treatment of chemonaiëve patients with stage III and IV non-small cell lung cancer (NSCLC), *lung cancer*, vol 49, suppl 2, july 2005, p382, page s271
90. Platinum based chemotherapy for patients (Pt) with Non Small Cell Lung Cancer (NSCLC) with anemia treated with Eupoetin beta or blood transfusion, a pilot study, *Annals of Oncology*, vol 14,2006 Su8pplement 4,p136
91. Andrea Ardizzoni¹, Evangelia Razis², Mikhail Lichinitser³, Ugur Yilmaz⁴, Alexandru C. Grigorescu⁵, José Luis Morero⁶, Jana Skrickova⁷, Guadalupe Cervantes⁸, Maya Gottfried⁹, Jan Van Meerbeeck¹⁰, *ASCO abstract Book* 2009.
92. Alexandru Grigorescu post peer review , DOI: 10.3410/f.718389158.793495548, 02 Jun 2014 ,Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, Pas TD, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsy-pin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H, Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial, *Lancet Oncol.* 2014 Jun; 15(7):713-21

93. Alexandru Grigorescu post peer review, DOI: 10.3410/f.718415927.793495708, 02 Jun 2014, Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, Tran-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ, A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer, *Eur J Cancer*. 2014 May 21
94. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718315380.793493332, 08 Apr 2014 ,Ritzwoller DP, Carroll NM, Delate T, Hornbrook MC, Kushi L, Bowles EJ, Loggers ET, Menter A, Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience, *J Thorac Oncol*. 2014 Mar 13
95. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718258092.793490636, 11 Mar. 2014, Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW, Riely GJ, Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC, *Ann Oncol*. 2014 Feb; 25(2):415-22
96. Alexandru Grigorescu ,post peer review , DOI: 10.3410/f.718163663.793491857 ,14 Mar 2014, Yin AA, Cai S, Dong Y, Zhang LH, Liu BL, Cheng JX, Zhang XA meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patient, *J Neurooncol*. 2014 Jan; 116(2):315-24
97. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718140888.793489232, 14 Jan 2014, Bernards N, Creemers GJ, Nieuwenhuijzen GA, Bosscha K, Pruijt JF, Lemmens VE, No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy, *Ann Oncol*. 2013 Dec; 24(12):3056-60
98. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718106825.793486609, 08, Nov 2013 Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP, AVEX study investigators, Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial, *Lancet Oncol*. 2013 Oct; 14(11):1077-85
99. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718026266.793481159 27 Aug 2013, Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM, Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non-Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial, *J Thorac Oncol*. 2013 Jul; 8(7):930-939
100. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718019529.793481158, 09 Aug 2013, Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, *Lancet Oncol*. 2013 Jul; 14(8):741-8
101. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718026279.793482141, 19 Aug 2013, Fietkau R, Lewitzki V, Kuhnt T, Hölscher T, Hess CF, Berger B, Wiegel T, Rödel C,

Niewald M, Hermann RM, Lubgan D , A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: Results of a randomized, controlled, multicenter trial, Cancer. 2013 Jun 13

102. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718016207.793479525, 18.Jul 2013 Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial, Lancet Oncol. 2013 Jun; 14(7):663-70

103. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.717973653.793479424, 18 Jul 2013 Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D, Isakoff S, Ciciliano J, Wells M, Shah A, Concannon K, Donaldson M, Sequist L, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber D, Maheswaran SCirculating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition, Science. 2013 Feb 1; 339(6119):580-4

104. Alexandru Grigorescu ,post peer review, DOI: 10.3410/f.718106504.793483715, 24 Sep 2013 Azmi A, Sarkar F, Hadi S, Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property [v1; ref status: indexed, <http://f1000r.es/15s>].

105. Valentin Titus Grigorean¹, Gabriela Rahnea Niță², Aurelia Mihaela Sandu³, Alexandru Grigorescu⁴, Anda-Natalia Ciuhu⁵, Mihai Popescu⁶, Blockage Of Communication With The Patient's Family – Clinical And Psycho-Emotional Implications, Acta Medica Transilvanica March 2014;2(1):127-130

106. Alexandru Calin Grigorescu, Long-term survivors in advanced non-small cell lung cancer treated sequentially with cytostatic drugs and erlotinib: A retrospective study Journal of Translational Internal Medicine, ISSN 2224,, Vol 2 | Issue 2 | Apr-Jun 2014, p 83-86

107. Alexandru Calin Grigorescu, Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest, Journal of Translational research, Issue 1, Jan-Mar 2015, p24-28.
doi:

108. Alexandru Calin Grigorescu review, DOI: 10.3410/f.725638359.793508418
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. Yamada K, Aono H, Hosomi Y, Okamoto H, Kato T, Komase Y, Nishikawa M, Azuma K, Takeoka H, Okuma Y, Nakahara Y, Sato A, Oba MS, Morita S, Kunitoh H, Watanabe K

109. Alexandru Calin Grigorescu, review (DOI: 10.3410/f.731932336.793537702): Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. Vahl JM, Friedrich J, Mittler S, Trump S, Heim L, Kachler K, Balabko L, Fuhrich N, Geppert CI, Trufa DI, Sopel N, Rieker R, Sirbu H, Finotto S

110. Alexandru Calin Grigorescu review (DOI: 10.3410/f.727384522.793529715) Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. Okamoto I, Schuette WH, Stinchcombe TE, Rodrigues-Pereira J, San Antonio B, Chen J, Liu J, John WJ, Zinner RG show author affiliations Curr Med Res Opin. 2017 Mar 12; 33(5):1-5
111. Alexandru Calin Grigorescu, DOI: 10.3410/f.718106825.793486609, Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP, AVEX study investigators show author affiliations Lancet Oncol. 2013 Oct; 14(11):1077-85
112. Grigorescu A: F1000Prime Recommendation of [Horn L et al., N Engl J Med 2018 379(23):2220-2229]. In F1000Prime, 11 Dec 2018; [10.3410/f.734066997.793553700](https://doi.org/10.3410/f.734066997.793553700)
113. Grigorescu A: F1000Prime Recommendation of [Grossi F et al., Eur J Cancer 2018 100:126-134]. In F1000Prime, 30 Jul 2018; [10.3410/f.733652114.793548529](https://doi.org/10.3410/f.733652114.793548529)
114. Grigorescu A: F1000Prime Recommendation of [Sim EH et al., Cochrane Database Syst Rev 2018 1:CD006847]. In F1000Prime, 08 Feb 2018; [10.3410/f.732499623.793542180](https://doi.org/10.3410/f.732499623.793542180)
115. A.C. Grigorescu, CDK inhibitors and PARP inhibitors in current clinical practice, Oncolog Hematolog, Anul XII • No. 42 (1/2018)
116. A.C. Grigorescu, Association between tyrosine kinase inhibitors (TKIs) and chemotherapy in non-small cell lung cancer, Oncolog Hematolog, Anul XII • No. 43 (2/2018)
117. A.C. Grigorescu, IMMUNOTERAPY OF PARTICULAR CANCER LOCALIZATIONS, A SHORT REVIEW, Oncolog Hematolog, Anul XII, Nr4493/2018)
118. A.C. Grigorescu, Oncolog Hematolog, Healthcare principles of end-of-life stage in oncologic diseases, Anul XII No. 45 (4/2018).
119. [Palliative care for end-of-life stage in oncologic disease](#)
AG Lucian Miron 2019
Oncolog Hematolog 45 (4), 27-30
120. [How to Integrate Medical Oncology and Palliative Care?](#)
ACGTL Mihaela2 2019
EC PULMONOLOGY AND RESPIRATORY MEDICINE 8, 29-31
[National screening for cervical cancer. Preliminary experience for breast cancer screening](#)
121. MMR V.M. Prunoiu¹, Oana Șaptefrați², Rossana Iuliana Brătucu³, Cristina 2019
...
Oncolog Hematolog 13 (49), 27-32
122. [Short review of immunotherapy with PD-1/PD-L1 inhibitors in non-small-](#)

- [cell 127 lung cancer \(NSCLC\)](#)
2019
ACG Mihaela Albu
Oncolog Hematolog 46 (1)
123. [Review of "Benefits and limitations of a multidisciplinary approach in cancer patient management."](#) 2020
AC Grigorescu
Faculty opinions 2020 (6)
124. [Guide to diagnosis and treatment of breast cancer](#) 2020
SM Alexandru C. Grigorescu
Oncolog Hematolog 52 (3/2020), 8-16
125. [Some Opinions on The Role of The Family Doctor in The Care of Cancer Patients- A Short Review](#) 2020
ACG Catalina Ciocirlan
BJSTR 32 (3), 25028-25030
126. [Systemic Adjuvant Therapy in Non-Small Cell Lung Cancer \(NSCLC\)](#) 2020
AC Grigorescu
EC PULMONOLOGY AND RESPIRATORY MEDICINE 9 (9), 35-42
127. [Recommendation, Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer \(SCLC\) \(NABSTER TRIAL\).](#) 2020
elsomino F Tiseo M Barbieri F Riccardi F Cavanna L Frassoldati A Delmonte A ...
Faculty opinions 2020, 10.3410/f.737847695.793574335
128. [Recommendation of "Cancer Therapy & Oncology International Journal"](#) 2020
A Grigorescu
F1000, 10.3410/f.737101363.793569080
129. [Recommendation: "First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost ..."](#) 2020
AC Grigorescu
F1000, 10.3410/f.736170538.793563121
130. [Treatment options for HER2-positive metastatic breast cancer](#) 2020
ACG C. Ciubotaru
Oncolog Hematolog 51 (2), 31-34
131. [Recommendation of "The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis."](#) 2020
AC Grigorescu
132. Faculty opinions, 10.3410/f.737668835.793573670
[Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting \(CINV\): Results of the Nausea/Emesis Registry in Oncology \(NERO\).](#) 2020
AG Matti S. Aapro, Marika Chr  pav  , Razvan-Ovidiu D. Curca, Laurentia Gales

- Journal of Clinical Oncology 38 (15), 12083-12083
133. [Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting \(CINV\): Results of the Nausea/Emesis Registry in Oncology \(NERO\).](#) 2020
AWC Matti S. Aapro, Marika Chr  pav  , Razvan-Ovidiu D. Curca, Laurentia Gales ...
Journal of Clinical Oncology 38 (15), 411
134. [EMERGENCY PALLIATION PROTOCOL FOR NON-VENTILATED COVID-19 PATIENTS – HOMECARE VERSION](#) 2020
[https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19 ...](https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19...)
135. [Introduction to the ESMO COVID-19 Palliative Care Pathways](#) 2020
[https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19 ...](https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage/covid-19...)
136. [Rules for the manipulation of cytostatic agents used in cancerous disease](#) 2020
AC Grigorescu
Oncolog Hematolog.ro 50 (1), 42-46
137. [Immunotherapy agents combination in metastatic melanoma – case presentation](#) 2020
CC Alexandru C. Grigorescu
Oncolog Hematolog.ro 50 (1), 28-31
138. [Tyrosine Kinase Inhibitors \(TKIs\) in the Treatment of Non–Small Cell Lung Cancer \(NSCLC\), Practical Pharmacological Aspects](#)
AC Grigorescu, LM Teodorescu
Journal of Drug Delivery and Therapeutics 10 (1), 135-138 2020
139. [Some Opinions on The Role of The Family Doctor in The Care of Cancer Patients- A Short Review](#) 2021
ACG Catalina Ciocarlan
Biomed J Sci & Tech Res | BJSTR. MS.ID.005255. 3 (1), 12083-12083
140. [Chronic Pulmonary Obstructive Disease \(COPD\) Implications in Lung Cancer Systemic Therapy](#) 2021
AC Grigorescu
EC PULMONOLOGY AND RESPIRATORY MEDICINE 10 (2), 40-43



09.04.2021